abcdefghijklmn
opqrstuvwxyz
Test Menu
Test Change Details
Allergy & Immunology
Cardiology & Coagulation
Dermatopathology
Endocrinology
Gastroenterology
Genetics
Hepatology
Infectious Disease
Microbiology
Nephrology
Neurology
Oncology
Pathology
Pediatrics
Rheumatology
Toxicology
Urology
Women's Health
16160: AccuType® Warfarin Print View
CYP2CP and VKORC1      

PRIMARY
1 Whole Blood EDTA 5 (3) mL   Room Temperature - 8 Day(s)/Refrigerated - 8 Day(s)  
ALTERNATE
  Whole Blood ACD Sol B 5 (3) mL   Room Temperature - 8 Day(s)/Refrigerated - 8 Day(s)  
  Whole Blood ACD Sol A 5 (3) mL   Room Temperature - 8 Day(s)/Refrigerated - 8 Day(s)  
  Whole Bld Heparin Lithium   Room Temperature - 8 Day(s)/Refrigerated - 8 Day(s)  
  Saliva   Refrigerated - 14 Day(s)/Room Temperature - 14 Day(s)  
  Sodium Heparin   Refrigerated - 8 Day(s)/Room Temperature - 8 Day(s)  
  WB NaHep Trace Metal   Refrigerated - 8 Day(s)/Room Temperature - 8 Day(s)  

Warfarin (Coumadinr) therapy is associated with significant complications because of its narrow therapeutic index and large interpatient dosage variation necessary to achieve an optimal therapeutic response. This variation is due to both genetic and environmental factors. A promoter variant (-1639 G>A) of the Vitamin K epoxide complex subunit 1 (VCR) accounts for 25%-44% of this variability and variants of the cytochrome P enzyme C (SPCA) account for 10%-15% of this variability. Identification of these warfarin sensitive variants of the VKORC1 and the CYP2C9 genes may allow a more individualized therapy and reduced risk of bleeding complications.
Setup Schedule
Monday, Wednesday, Friday

Reported (Analytical Time)
6 days

CPT Codes
81227+WA,81355

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Notes
METHODOLOGY: Single Nucleotide Primer Extension LIMITATIONS: Variations in two genes (VKORC1 and CYP2C9) are particularly important in warfarin metabolism. VKORC1 may explain 30% of the variability in drug response between patients and changes in CYP2C9 may explain 10% of the dose variation. While significant portion of the dose variability can be accounted for by genetic factors, this testing will not determine all factors associated with dose variability. *The 2012 AMA CPT codebook contains Tier 1 and Tier 2 Molecular Pathology Procedures as well as Molecular Pathology Procedures to be coded by procedure rather than analyte. Please direct any questions regarding coding to the payor being billed.






© 1996 - 2017 Quest Diagnostics Nichols Institute of Valencia
For test information, please call Client Services at 800-421-4449.

San Francisco Web Design & Database